Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
Nature Medicine
|
January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh, Melody Smith, Scott E James, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Science Translational Medicine
|
February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Marco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood Cancer Discovery
|
May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Neeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
Nature Medicine
|
March 14, 2023
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.
Blood
|
October 23, 2024
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy
Rishika Prasad, Abdur Rehman, Lubna Rehman, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
Nature Medicine
|
January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh, Melody Smith, Scott E James, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Science Translational Medicine
|
February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Marco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood Cancer Discovery
|
May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Neeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
Nature Medicine
|
March 14, 2023
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.
Blood
|
October 23, 2024
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy
Rishika Prasad, Abdur Rehman, Lubna Rehman, et al.
Page
of 10